KRA-533 |
Catalog No.GC64558 |
KRA-533은 강력한 KRAS 작용제입니다. KRA-533은 KRAS 단백질의 GTP/GDP 결합 포켓에 결합하여 GTP 절단을 방지하여 구성적으로 활성인 GTP 결합 KRAS가 축적되어 암세포에서 세포사멸 및 자가포식 세포 사멸 경로를 모두 유발합니다.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 10161-87-2
Sample solution is provided at 25 µL, 10mM.
KRA-533 is a potent KRAS agonist. KRA-533 binds to the GTP/GDP binding pocket in the KRAS protein to prevent GTP cleavage, resulting in the accumulation of constitutively active GTP-bound KRAS that triggers both apoptotic and autophagic cell death pathways in cancer cells.
KRA-533 (10 μM; 48 hours; HCC827 cells) enhances KRAS activity to a greater extent[1].KRA-533 (0~15 μM; 48 hours; H157 cells) enhances KRAS activity in a dose-dependent manner, which is associated increased levels of pERK, ratio of active caspase 3/procaspase 3 and PARP cleavage, leading to apoptotic cell death[1].KRA-533 (10 μM; 10 days; H292 cells) mediates cell growth suppression than those without KRAS mutation. KRA-533 (5~15 μM) can directly bind to WT, G12C, G12D and G13D mutant KRAS proteins. KRA-533 activates WT KRAS to increase its activity in a dose-dependent manner. KRA-533 further enhances the activities of active KRAS mutants[1].
KRA-533 (0~30 mg/kg; 28 days) suppresses tumor growth in a dose-dependent manner in lung cancer mutant KRAS xenografts and induces apoptosis and autophagy in tumor tissues in a dose-dependent manner[1].KRA-533 shows optimal therapeutic index between 7.5 mg/kg and 30 mg/kg doses[1].
[1]. Xu K, et al. Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy [published correction appears in Mol Cancer. 2020 May 20;19(1):93]. Mol Cancer. 2019;18(1):85. Published 2019 Apr 10.
Average Rating: 5
(Based on Reviews and 30 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *